Replies to post #318189 on Amarin Corp Plc (AMRN)

[mrmainstreet]

Raf, does your buddy think the case will deter other generics from launching while they wait and see, or will the just push on and join the crowd?

[HinduKush]

Yes, everyone is treading water in a wait and see and delay tactic mode. I think your friend has the measure of it.

[Biobillionair]

Thanks RAF for sharing. Hikma did take the party line and they posted their brief 7 weeks earlier than the extended due date. Attorneys rarely file 7 weeks earlier for no reasons...Hikma has strategy....

Amarin can absolutely kill Hikma’s pathetic dismissal brief with oxidation evidence. It exposes a dangerous API that is NOT AB rated and is being fed to literally 1000s of cardiovascular patients. Amarin needs to bring it or fold shop in US.

BB

[Crikker]

Thanks RAF. That analysis makes a lot of sense. Does he really think GSK vs Teva will be overturned? Said decision being upheld was possible but unlikely?
Please pass along my thanks for the analysis

[Gbert]

Hikma takes the expected party line which is "there is no case here, carving out indications is an essential part of industry/precedent, and that's all WE are doing. The only way WE could do anything wrong is if WE were actively encouraging the use of vascepa for non-MARINE patients, and WE don't do that at all. This is an easy dismissal".

I found it interesting that he used the word WE....sounds like he from inside Hikma?

As I suggested before - let all of the generics compete for the Marine Carve out allowed to them. They can cannibalize each other. They are responsible for the amount/API they order for sales. Amarin keeps track (they will too) that they don’t oversupply the market.... if they do... they get sued for infringement.

Or.....

Have Amarin make a new R-IT bottle/packaging for all of there supply - should account for >90% of the scripts and forget the Marine market.

Let generics compete with gL for high TGs...

Get those 800 Reps active on education of the inferior generic V, the “new” Reduce it packaging, and need to write the script the proper way to ensure patients are getting quality, life saving product.